Bliss GVS Pharma Limited — Interim / Quarterly Report 2021

Oct 30, 2021

BLISS GVS PHARMA LTD.

October 30, 2021

To	To
The Manager, Listing Department	The General Manager, Listing Department
National Stock Exchange of India Ltd.	BSE Limited
Plot no. C/1 G Block,	Phiroze Jeejeebhoy Towers,
Complex, Bandra (East), Bandra-Kurla	Dalal Street,
Mumbai- 400 051	Mumbai- 400 001
Symbol: BLISSGVS	Scrip Code: 506197

Subject: Outcome of Board Meeting held on Saturday, October 30, 2021

Dear Sir/Madam,

We would like to inform you that, Board Meeting of the Company was held today i.e. Saturday, October 30, 2021 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the following matters:

• 1. The Unaudited Standalone and Consolidated Financial Results for the quarter and half yearly ended September 30, 2021. A copy of unaudited financial results along with the Limited Review Report of the Auditors of the Company are enclosed herewith as 'Annexure - I'.
• 1. Sale of shares of Bliss GVS Clinic Healthcare Pte. Ltd., Singapore, Wholly Owned Subsidiary of the Company. Bliss GVS Clinic Healthcare Pte. Ltd is not material subsidiary of the Company. Consequent to this transaction, Bliss GVS Clinic Healthcare Pte. Ltd. will ceased to be the Subsidiary of the Company. Details of Transactions are enclosed herewith as' Annexure - II'.

The meeting of the Board of Directors commenced at 12:30 p.rn. and concluded at 17:30 p.m.

Kindly take the above information on your record and acknowledge

Thanking you.

Yours Faithfully,

For Bliss CVS Pharma Limited

Encl: As above

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA. TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930, Email: info@blissgvs.com •Website: www.blissgvs.com • CIN - L24230MH1984PLC034771 Factory: Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar,Aliyali Village, Tai. & Dist. Palghar-401 404. Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. •Email: factory@blissgvs.com

$A$ merwe-I

BLISS GYS PHARMAL INTED
Regional Phage (Office - 102, Hyde Park, Sakinaka Road, Andheri East- Mumbai-400072
Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September

					Standalone							Consolidated		(₹in Lakh)
	Sr. No	Particulars		Quarter Ended		Half Year Ended		Year Ended		Quarter Ended		Half Year Ended		Year Ended
			Sept 30, 2021 Un-Audited	June 30, 2021 Un-Audited	Sept 30, 2020 Un-Audited	Sept 30, 2021 Un-Audited	Sept 30, 2020 Un-Audited	Mar 31, 2021 Audited	Sept 30, 2021 Un-Audited	June 30, 2021 Un-Audited	Sept 30, 2020 Un-Audited	Sept 30, 2021 Un-Audited	Sept 30, 2020 Un-Audited	Mar 31, 2021 Audited
		Revenue from Operations	17,442.83	13,303.05	11,401.88	30,745.88	23,284.38	46,551.31	19,598.74	16,814.54	12,955.00	36,413.28	28,109.06	57,720.54
	$\equiv$ $=$	Total Income (I+II) Other Income	598.66 18,041.49	14,092.59 789.54	695.12 12,097.00	1,388.20 32,134.08	1,013.00 24,297.38	48,319.56 1,768.25	545.00 20,143.74	17,596.26 781.72	704.15 13,659.15	37,740.00 1,326.72	978.25 29,087.31	2,022.44 59,742.98
	$\geq$	Cost of Materials consumed Expenses	10,820.77	7,228.50	3,738.06	18,049.27	9,495.24	21,565.36	11,548.08	8,312.65	4,454.94	19,860.73	11,895.47	26,025.56
	ம் க்	Purchase of Stock-in-Trade	(17.54)	215.78	3,129.37	198.24	3,670.08	4,649.73	468.27	1,384.46	3,657.82	1,852.73	5,201.64	8,133.83
	ق	Changes in inventories of work in process, finished goods and stock in trade	(1, 263.98)	(610.10)	69.32	(1,874.08)	(312.27)	(884.72)	(1, 420.51)	(1, 021.11)	(117.59)	(2,441.62)	(983.30)	(1, 187.51)
	d	Employee Benefits Expense	1,641.09	1,538.22	1,409.14	3,179.31	2,776.68	5,860.93	1,893.68	1,773.97	1,603.23	3,667.65	3,175.51	6,809.21
	e,	Finance Costs	53.50	130.05	151.99	183.55	155.39	419.39	67.52	139.86	194.30	207.38	232.28	551.37
	÷	Depreciation and Amortisation Expense	344.64	348.13	342.88	692.77	688.24	1,376.22	429.66	433.41	428.65	863.07	859.82	1,722.97
	ŵ	Other Expenses	2,986.00	2,337.58	1,215.55	5,323.58	3,156.58	6,213.98	4,168.40	2,904.43	1,397.35	7,072.83	3,660.11	7,274.85
		Total Expenses	14,564.48	11,188.16	10,056.31	25,752.64	19,629.94	39,200.89	17,155.10	13,927.67	11,618.70	31,082.77	24,041.53	49,330.28
	5 $\,>$	Profit before exceptional Items and tax Exceptional Items $(III-N)$	3,477.01	2,904.43	2,040.69	6,381.44	4,667.44	9,118.67	2,988.64	3,668.59	2,040.45	6,657.23	5,045.78	10,412.70
	$\overline{\overline{5}}$	Profit before Tax (V-VI)	3,477.01	,904.43	2,040.69	6,381.44	4,667.44	9,118.67	2,988.64	3,668.59	2,040.45	6,657.23	5,045.78	10,412.70
	ξ	iii. Short/ Excess Provision of earlier years ii.Deferred Tax Liability/(Asset) Tax Expense i.Current Tax	(85.40) 983.37 106.30	640.07 98.56	(63.80) 394.88	1,623.44 13.16 106.30	1,075.74 3.37	2,152.43 116.89 99.27	(413.20) 1,089.62 106.30	955.29 98.79 1.37	(61.40) 436.79	(314.41) 2,044.91 107.67	1,213.02 6.67	2,604.29 123.29 287.96
NBA		Net Profit for the period	2,472.74	2,165.80	1,709.61	4,638.54	3,588.33	6,750.08	2,205.92	2,613.14	1,665.06	4,819.06	3,826.09	7,397.16
÷		(i) Remeasurement of the defined benefit liabilities/ (asset) (ii) Deferred tax on remeasurement of defined benefits i. Items that will not be reclassified to profit & loss Other Comprehensive Income (abilities/ (assets)	(13.59) 3.42	(3.76) 14.94	(45.99) 11.58	$1.35$ (0.34)	62.76 (16.02)	(17.62) 70.02	(13.59) 3,42	(3.76) 14.94	(45.99) 11.58	(0.34) 1.35	$62.76$ (16.02)	(17.62) 70.02
		(i) Exchange differences in translating the financial statements of ii. Items that will be reclassified to profit & loss foreign operations							30.47	(110.23)	225.47	(79.76)	(329.95)	(138.56)
		(ii) Deferred tax relating to items that will be reclassified to profit or loss							(7.67)	27.74	(159, 70)	20.07	95.19	34.87
	$\bar{x}$	Total Comprehensive Income for the period	2,462.57	2,176.98	1,675.20	4,639.55	3,635.07	6,802.48	2,218.55	2,541.83	1,696.42	4,760.38	3,638.07	7,345.87
	$\bar{x}$	ii. Non-controlling interests i. Owners of the Company Profit attributable to:		$\bullet$ $\qquad$	$\alpha$		$\kappa$ = $\kappa$		2,126.62 79.30	2,425.42 187.72	1,619.20 45.86	4,552.04 267.02	3,669.82 156.27	6,849.09 548.07
narma s	ΧIII	Other Comprehensive income attributable to: ii. Non-controlling interests i. Owners of the Company	$x = x$	$\epsilon$					15.19 (2.56)	(73.63) 2.32	30.76 0.60	(58.44) (0.24)	(190.55) 2.53	(53.07) 1.78
	XIV	Total Comprehensive income attributable to: ii. Non-controlling interests i. Owners of the Company							2,141.81 76.74	2,351.79 190.04	1,649.96 46.46	4,493.60 266.78	3,479.27 158.80	6,796.02 549.85
	XV	Paid up equity share capital (Face Value - ₹ 1/-each)	1,035.09	1,033.57	1,031.47	1,035.09	1,031.47	1,031.47	1,035.09	1,033.57	1,031.47	1,035.09	1,031.47	1,031.47
	$\overline{\mathbf{x}}$	Earnings Per Share Basic & Diluted (Not Annualised) i. Basic ii. Diluted	2.39 2.34	2.10	$1.66$ $1.62$	4.48 4.38	3.48 3.41	6.54 6.40	2.05 2.01	2.35	$1.57$ $1.54$	4,30 4,30	3.56 3.48	6.649

BLISS GVS PHARMA LIMITED

Regd. Office - 102, Hyde Park, Sakinaka Road, Andheri East- Mumbai-400072

Balance Sheet as at September 30, 2021

(~ in Lakh) Consolidated
			Mar 31, 2021
			Audited
			22,542.85
			239.49
			68.93
			771.11
			57.85
1,829.80	1,829.80	219.08	1.00
	2.49	1.96	2.74
	6,391.73	5,799.62	6,407.97
	955.90	2,794.28	1,066.68
	26,897.86	35,376.70	31,158.62
			9,892.74
			46,382.03
			1,263.47 13,191.59
			15.54
			1,612.00
			142.71
			4,019.88
	67,664.21	80,636.82	76,519.96
1,03,903.15	94,562.07	1,16,013.52	1,07,678.58
			1,031.47
			79,793.88 1,965.60
	3,249.09	2,773.65	3,260.39
	182.91		182.91
			249.75
			820.91 10.09
			4,524.05
	5,637.45	6,629.19	8,614.83
			1,011.89
			6,410.58
			131.82
			1,325.10
	914.31	1,087.55	1,800.65
	159.25	1,719.84	866.08
	-	693.19	202.63
			20,363.58 1,07,678.58
(d) Current tax liabilities (Net)	Un-Audited (a) Property, Plant and Equipment - 30,342.41 36,866.74 (111) Bank balances other than (ii) above 10,244.68 7,296.20 2,352.63 - 1,035.09 79,221.67 - 528.60 (c) Deferred tax liabilities (Net) 718.41 liabilities - (A) Total outstanding dues of micro enterprises and small enterprises 982.69 dues of other than and small enterprises 2,177.11 19,386.44 1,03,903.15	Standalone Mar 31, 2021 Sept 30, 2021 Audited 19,916.44 17,356.14 803.90 239.49 68.85 68.93 - 44.18 53.38 1.96 5,085.00 2,592.28 11,122.74 8,367.69 34,868.09 479.44 420.99 11,530.92 6,488.30 2,220.87 38.92 5,198.31 3,728.43 73,560.74 1,031.47 74,533.27 - 2,768.40 244.54 249.75 704.91 - 4,259.95 4,386.66 4,141.29 535.55 10,312.34 6,141.98 163.56 114.51 1,107.62 430.98 749.46 429.01 14,610.67 94,562.07	Sept 30, 2021 Un-Audited 24,858.40 815.46 68.86 771.11 47.93 12,971.69 45,187.95 2,140.37 11,083.53 16.60 1,592.94 - 7,643.74 1,035.09 84,336.33 2,226.98 533.06 244.54 521.63 9.42 4,082.30 1,175.68 10,491.99 180.29 2,355.09 24,332.82 1,16,013.52

BLISS GVS PHARMA LIMITED

Regd. Office - 102, Hyde Park, Sakinaka Road, Andheri East-Mumbai-400072 Statement of Cash Flows for the Half Year Ended September 30, 2021

		Standalone			Consolidation
	Half Year Ended		Year Ended	Half Year Ended		Year Ended
Particulars	Sept 30, 2021	Sept 30, 2020	Mar 31, 2021	Sept 30, 2021	Sept 30, 2020	Mar 31, 2021
	Un-Audited	Un-Audited	Audited	Un-Audited	Un-Audited	Audited
A. CASH FLOW FROM OPERATING ACTIVITIES
Net Profit before Tax	6,381.44	4,667.44	9.118.67	6,657.23	5,045.78	10,412.70
Add/(Less):
Depreciation and amortisation expense	692.77	588.24	1,376.22	863.07	859.82	1,722.97
Finance costs	183.55	155.39	419.39	207.38	350.02	551.37
Interest Income	(551.48)	(501.13)	(1,095.75)	(440.05)	(442.91)	(957.84)
Provision for Employee Benefits	41.97	36.90	73.79	41.97	36.90	83.79
(Profit) /loss on sale/scrap/written off of fixed assets (Net)	(3.17)	(2.86)	3.08	(3.18)	(2.86)	3.08
(Gain)/ Loss on foreign exchange fluctuations (net)	(454.07)	(1, 423.96)	1,776.56	(488.80)	(1,423.96)	1,664.64
Dividend income	(12.60)
Bad debts written off	169.33	64.43	154.95	169 33	64.43	154.95
Allowance and Provision for Doubtful Debts	764.70	282.81	240.79	764.70	282.81	240.79
Balance Written off/back and other non cash item	44.72	42.17	181.63	44.73	42.17	181.63
Share based payment expenses	341.57	467.83	983.76	341.57	467.83	983.76
	1,217.29	(190.18)	4,114.42	1,500.72	234.25	4,629.14
Operating profit before working capital changes	7,598.73	4,477.26	13.233.09	8,157.95	5,280.03	15,041.84
Movements in Working Capital:
Trade Receivables	(2,691.59)	5,843.75	3.505.85	549.57	5,127.49	6,292.56
Inventories	(2,765.57)	(660.42)	(2, 511.43)	(3,089.48)	(1.227.26)	(2,680.11)
Loans and Other Financial Assets	1,408.38	(7.87)	(6, 160.77)	67.86	(454.60)	(6, 257.64)
Other assets	(1,530.85)	(6, 392.23)	(901.65)	(2,869.44)	126.08	(695.09)
Trade Payables	4,627.84	(884.79)	1,184.59	4,241.84	(2, 479.37)	(1,467.62)
Other Financial Liabilities	524.72	(122.73)	109.77 509.19	462.47 (484.17)	101.65 2,756.76	589.39 (1,570.11)
Other Liabilities and Provisions	(392.31)	436.31	(4, 264.45)	(1, 121.35)	3,940.75	(5,788.62)
	(819.38) 6,779.35	(1,787.98) 2.689.28	8,968.64	7,036.60	9,220.78	9,253.22
Cash generated from operations Income taxes paid/refund (net)	(1, 281.40)	(1,015.99)	(2, 271.92)	(1, 413.26)	(1, 542.78)	(2,856.28)
Net Cash Flow from Operating Activities	5,497.95	1,673.29	6,696.72	5.623.34	7,678.00	6,396.94
B. CASH FLOW FROM INVESTING ACTIVITIES
Payments to acquire Property, Plant and Equipment and CWIP	(4, 412.46)	(325.57)	(805.91)	(4, 334, 39)	(41.67)	(912.42)
Proceeds from sale of Property, Plant and Equipment	33.00	6.93	42.07	33.46	8.21	42.06
(Increase)/ Decrease in Other Bank Balances	1,286.24	(1,617.51)	(3,946.27)	2,108.06	(8,682.56)	(4,368.89)
Interest received	344.32	236.07	463.75	232.89	892.36	538.69
Dividend received	12.60		$\frac{1}{2}$
Investment made				(218.08)	$\overline{a}$
Loan given to Subsidiaries	(740.86)	1.47	(1, 915.69)			1.46
Net Cash Flow used in Investing Activities	(3,477.16)	(1,699.61)	(6, 162.05)	(2, 178.06)	(7,823.66)	(4,699.10)
C. CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from secured borrowings	888.28	1,683.12	1,936.41	887.78	1,524.01	966.50
Repayment of secured borrowings	(2,899.54)	(1,754.09)	(1, 711.12)	(3, 394.57)	(823.33)	(1,634.18)
Payment of Lease liabilities	(115.46)	(117.66)	(219.90)	(133.87) (179.54)	(129.70) (329.28)	(225.20) (631.97)
Finance cost paid	(174.23)	(135.35)	(617.73) (554.95)	(5.40)	(9.80)	(554.95)
Dividend paid	155.77	(9.80)		155.77
Proceeds from issue of shares including securities premium Share Application money received	72.67			72.67
Net Cash Flow used in Financing Activities	(2,072.51)	(333.78)	(1, 167.29)	(2,597.16)	231.90	(2,079.80)
Net increase in cash and cash equivalents (A+B+C)	(51.72)	(360.10)	(632.62)	848.12	86.24	(381.96)
Cash and cash equivalents at the beginning of the year	467.10	1,099.72	1,099.72	1,313.45	1,533.95	1,533.95
Effect of exchange on restatement of foreign currency			$\overline{\phantom{a}}$	44.95	(224.98)	161.46
Cash and cash equivalents at the end of year*	415.38	739.62	467.10	2,206.52	1,395.21	1,313.45
*Including balance of ₹ 66.15 Lakh (Previous Period ₹ 37.08 Lakh) (Year ended March 31, 2021 ₹ 49.94 Lakh) with gratuity bank account and unrealised exchange flutuation.
Notes:

$\frac{1}{8121}$ Pha û. Mumbai GS. $\frac{1}{\sqrt{2}}$

Notes:

• ¹The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on Oct 30, 2021. The financial results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules in this regard.
• 2 The current quarter results have been subject to a limited review by the statutory auditors of the company. The statutory auditors, Kalyaniwalla & Mistry LLP have issued report with unmodified opinion on the standalone and consolidated financial results.
• 3 As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed.
• 4 The Group continues to monitor the impact of Covid 19 on its business, including its impact on customers, supply-chain, employees and logistics. The Group doesn't expect any material impact on this account.
• 5 Employee Benefit Expenses includes Share Based Payment on account of ESOP Scheme, 2019 of~ 341.57 Lakh (Previous Period ~ 467.83 lakh) as per Ind AS 102 for the half year ended Sept 30, 2021.
• 6 During the half ended September 30, 2021, the company has alloted 3,62,250 equity shares of~ 1 each fully paid, on exercise of stock options by employees in accordance with the company's ESOP scheme, 2019. From the total number of options granted 34,85,000 the outstanding number of options as at September 30, 2021 are 23,80,250 including 1,69,000 shares for which application money is received pending allotment.
• ⁷The figures for the quarter ended September 30, 2021 are the balancing figures between unaudited figures in respect of the half year ended September 30, 2021 and the year to date published figures for the quarter ended June 30, 2021.

Place : Mumbai Date: Oct 30, 2021

^IKey Highlights for Standalone FY 2021-22 Hl (Sept'2021)

^IKey Highlights for Consolidated FY 2021-22 Hl (Sept'2021)

KALYANIWALLA & MISTRYLLP

CHARTERED ACCOUNTANTS

To, The Board of Directors, Bliss GVS Pharma Limited, 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai 400 072.

LIMITED REVIEW REPORT

• 1. We have reviewed the accompanying Statement of unaudited standalone financial results of Bliss GVS Pharma Limited ('the Company'), for the quarter and half ended September 30, 2021 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations") (initialed by us for identification).
• 1. This Statement, which is the responsibility of the Company's Management has been reviewed by the Audit Committee and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
• 1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SREs) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
• 1. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

LLP IN: AAH · 3437 REGISTERED OFFICE: ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001 TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

1. We draw attention to our reliance on the management representation in respect of the recoverability of the Company's investment in, loans given to, Interest accrued thereon and Trade receivables from one of its subsidiary and its step-down subsidiary aggregating to Rs. 4,673.47 Lakh.

Our conclusion is not modified in respect of this matter.

For KALY ANIW ALLA & MISTRY LLP CHARTERED ACCOUNTANTS Firm Registration No. 104607W/W100166

Sai Venkata Ramana Damarla Partner Membership No. 107017 UDIN:~ IID1o(f A-Prf.A f> i.R. 1-rr ·. Place: Mumbai Dated: October 30, 2021.

KALYANIWALLA & MISTRYLLP

CHARTERED ACCOUNTANTS

To, The Board of Directors, Bliss GVS Pharma Limited, 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai -400 072.

LIMITED REVIEW REPORT

• 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Bliss GVS Pharma Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended September 30, 2021 ("the Statement"),attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations") (initialed by us for identification).
• 1. This Statement, which is the responsibility of the Parent's Management has been reviewed by the Audit Committee and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (''Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
• 1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SREs) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

1. The Statement includes the financial results of the following entities:

A. Incorporated in India:

1. Kremoint Pharma Private Limited, India 1.1. Eipii Exports PrivateLimited, India

L L P I N : AA H - 3 4 3 _?

REGISTERED OFFICE : ESPLA.N·ADE HOUSE, 29, HAZA'R'IMAL SOMANI MARG, FORT, MUMBAI 400 001 TE L . ; ( 9·1 ) { Cl' 2} 6 I 5 8 6 2 O O , 6 1 5 8 7 2 O O F A X : ( 9 1 ) ( 2 2 ) 6 I 5 8· 6 2 7 5

B. Incorporated outside India:

• 1. Bliss GVS International Pte. Ltd., Singapore
• 2.1. Greenlife Bliss Healthcare Limited, Nigeria
• 1. Bliss GVS Clinic Healthcare Pte. Ltd., Singapore
• 1. Asterisk Lifesciences Limited (UK), United Kingdom

4.1. Asterisk Lifesciences (GH) Limited, Ghana

• 1. Based on our review procedures conducted as mentioned above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
• 1. We did not review the interim financial information of 7 subsidiaries included in the statement, whose financial results reflect the Group's share for the quarter and half year ended September 30, 2021 for the under mentioned items. These interim financial statements and other financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's Management, and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and to the extent, they have been derived from such financial statements is based on the report of such other auditors.

		(In Lakh)
Particulars	Quarter Ended September 30, 2021	Half Year Ended September 30, 2021
Total Assets	12,110.37	12,110.37
Total Revenue	2,155.91	5,667.40
Profit After Tax	(266.82)	180.52
Total Comprehensive Income	(244.02)	120.83
Net Cash outflows I (inflows)	NA	(899.84)

Our conclusion on the Statement is not modified in respect of the above matter.

For KAL Y ANIW ALLA AND MISTRY LLP CHARTERED ACCOUNTANTS Firm Registration No. 104607W/W100166

Sai Venkata Ramana Damarla

Annexure - II

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are provided below:

No.	Particulars	Remarks
a)	Name of the Subsidiary whose shares are to be disposed off by the Company	Bliss GVS Clinic Healthcare Pte. Ltd., Singapore ('Wholly Owned Subsidiary')
b)	and percentage The amount of the revenue or turnover contributed by such unit or division of the listed entity during the last financial year i.e. March 31,2021	Revenue of the Subsidiary - Nil % of Consolidated Turnover: NA
c)	Date on which the agreement for sale has been entered into	On or before January 31, 2022
d)	the expected date of completion of sale/ disposal
e)	consideration received from such sale/ disposal	Not less than 3,75,000 USD
f)	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/ gi·oup companies. If yes, details thereof	Medylife Global FZE is an International Company having business of Trading and Distribution of Pharma related chemicals and not related to promoter/ supply promoter group/ group companies.
g)	whether the transaction would fall within related party transactions? If whether the same done at yes, is "arm' s length"	Not Applicable
h)	additionally, in case of a slump sale, disclosures indicative provided for amalgamation/ merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable